Capula Management Ltd Buys New Shares in Qiagen N.V. $QGEN

Capula Management Ltd bought a new position in Qiagen N.V. (NYSE:QGEN) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 27,820 shares of the company’s stock, valued at approximately $1,114,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Boston Partners bought a new position in shares of Qiagen in the third quarter worth about $179,450,000. Norges Bank bought a new stake in Qiagen during the 4th quarter valued at approximately $166,500,000. Dimensional Fund Advisors LP bought a new stake in Qiagen during the 3rd quarter valued at approximately $58,079,000. Price T Rowe Associates Inc. MD lifted its holdings in Qiagen by 12.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock worth $379,072,000 after purchasing an additional 906,589 shares in the last quarter. Finally, Deutsche Bank AG boosted its stake in Qiagen by 9.7% in the 4th quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock worth $355,614,000 after purchasing an additional 697,342 shares during the period. 70.00% of the stock is owned by institutional investors.

Qiagen Trading Up 2.1%

Shares of QGEN opened at $41.43 on Friday. The stock has a market capitalization of $8.54 billion, a PE ratio of 21.64, a P/E/G ratio of 4.05 and a beta of 0.64. The company’s fifty day moving average is $37.96 and its 200 day moving average is $42.14. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.57 and a current ratio of 3.21. Qiagen N.V. has a fifty-two week low of $32.53 and a fifty-two week high of $57.81.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.54 EPS for the quarter, meeting the consensus estimate of $0.54. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. The business had revenue of $492.32 million during the quarter, compared to analyst estimates of $496.15 million. During the same quarter last year, the business earned $0.56 earnings per share. Sell-side analysts expect that Qiagen N.V. will post 2.43 earnings per share for the current fiscal year.

Qiagen Increases Dividend

The firm also recently declared an annual dividend, which was paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th were issued a $0.35 dividend. This represents a dividend yield of 90.0%. The ex-dividend date of this dividend was Tuesday, July 7th. This is a positive change from Qiagen’s previous annual dividend of $0.26. Qiagen’s payout ratio is 18.32%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on QGEN shares. Barclays set a $38.00 price objective on shares of Qiagen and gave the company an “equal weight” rating in a report on Wednesday, April 29th. Robert W. Baird set a $43.00 target price on shares of Qiagen and gave the stock an “outperform” rating in a research report on Wednesday, April 29th. Zacks Research upgraded shares of Qiagen from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 29th. JPMorgan Chase & Co. decreased their price target on shares of Qiagen from $60.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 29th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $43.00 price objective on shares of Qiagen in a research report on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $43.34.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.